Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo.
Adv Sci (Weinh)
; 11(25): e2401710, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38582513
ABSTRACT
Corneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression. CRISPR offers a novel opportunity to treat CNV. This study shows that depletion of VEGFA with a novel CRISPR/Cas9 system inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Importantly, subconjunctival injection of this dual AAV-SpCas9/sgRNA-VEGFA system is demonstrated which blocks suture-induced expression of VEGFA, CD31, and α-smooth muscle actin as well as corneal neovascularization in mice. This study has established a strong foundation for the treatment of corneal neovascularization via a gene editing approach for the first time.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Corneal Neovascularization
/
Vascular Endothelial Growth Factor A
/
Disease Models, Animal
/
Human Umbilical Vein Endothelial Cells
/
CRISPR-Cas Systems
/
Gene Editing
Limits:
Animals
/
Humans
Language:
En
Journal:
Adv Sci (Weinh)
Year:
2024
Document type:
Article
Affiliation country:
Publication country:
ALEMANHA
/
ALEMANIA
/
DE
/
DEUSTCHLAND
/
GERMANY